Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

In April 2024, the journal Blood Science published an important study led by Dr. Gang An and colleagues from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigating the use of subcutaneous daratumumab in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). Multiple myeloma is a challenging hematological malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Despite significant advances in treatment, many patients experience relapse or develop resistance to existing therapies, necessitating new and more effective approaches.
Breaking the Barrier of Immunotherapy Consolidation, ALK-TKI Combined with CRT Might Transform the Standard Treatment for Unresectable ALK-Positive

Breaking the Barrier of Immunotherapy Consolidation, ALK-TKI Combined with CRT Might Transform the Standard Treatment for Unresectable ALK-Positive

The American Society for Radiation Oncology (ASTRO) Annual Meeting took place in Washington, D.C., from September 29,2024 to October 2,2024. As one of the most prestigious annual events in radiation oncology, ASTRO offers a platform to share the latest advances, focusing on radiotherapy as a primary treatment for various cancers, alongside key updates in technology and basic research.
Dr. Lorusso comments on the OS results of KEYNOTE-A18 study: There is a new standard for the treatment of locally advanced high-risk cervical cancer

Dr. Lorusso comments on the OS results of KEYNOTE-A18 study: There is a new standard for the treatment of locally advanced high-risk cervical cancer

The data of the KEYNOTE-A18 study disclosed at the Presidential Symposium I of the 2024 ESMO Congress shows that the overall survival (OS) of newly diagnosed patients with locally advanced cervical cancer who received pembrolizumab and concurrent chemoradiotherapy (CRT) is significantly improved (abstract number 709O). The 36-month OS rate of pembrolizumab + concurrent CRT treatment is 82.6%, and the 36-month OS rate of placebo + concurrent CRT treatment is 74.8% (hazard ratio [HR]=0.67; 95% confidence interval [CI]: 0.50–0.90; P=0.0040). The median OS has not been reached in both treatment groups. The survival benefit is consistent in all prespecified subgroups. At a median follow-up of 29.9 months, the 36-month progression-free survival (PFS) rates of the pembrolizumab group and the placebo group are 69.3% and 56.9%, respectively, and the median PFS is still NR (HR=0.68; 95% CI: 0.56-0.84). The incidences of grade ≥3 treatment-related adverse events in the two treatment groups are 69.1% and 61.3%, respectively. Quality of life (QOL) is not affected. At week 36, using the EORTC QLQ-C30 quality of life index questionnaire, no clinically significant differences between groups are reported.
ESMO 2024丨Dr. González-Martín interprets the final analysis results of the PRIMA/ENGOT-ov26/GOG-3012 study

ESMO 2024丨Dr. González-Martín interprets the final analysis results of the PRIMA/ENGOT-ov26/GOG-3012 study

Dr. Antonio González-Martín from the Cancer Center Clínica Universidad de Navarra in Spain presented the results of the phase III PRIMA/ENGOT-OV26/GOG-3012 study (abstract number LBA29) at the 2024 ESMO Congress. For patients with advanced ovarian cancer with homologous recombination deficiency (HRd), the possibility of progression-free survival after treatment with niraparib is twice that of placebo, although the study did not report long-term overall survival (OS) benefit. Oncology Frontier invited Dr.Antonio González-Martín on site to analyze the clinical significance of this research finding.
ESMO 2024 丨 Dr. Jennifer Chan: The CABINET trial adds a major new treatment “weapon” for patients with advanced neuroendocrine tumors

ESMO 2024 丨 Dr. Jennifer Chan: The CABINET trial adds a major new treatment “weapon” for patients with advanced neuroendocrine tumors

The CABINET study (abstract number 11410), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), updated the latest results of cabozantinib versus placebo in the treatment of advanced neuroendocrine tumors (NETs) after progression following previous treatment. At the conference site, we specially invited the Principal Investigator, Dr. Jennifer Chan from the Dana-Farber Cancer Institute in Boston, to be interviewed by us on site.
Dr. Lorenza Rimassa: The 5-year OS update of the HIMALAYA study sets a new high for survival in first-line treatment of advanced liver cancer

Dr. Lorenza Rimassa: The 5-year OS update of the HIMALAYA study sets a new high for survival in first-line treatment of advanced liver cancer

Immunotherapy for advanced liver cancer has advanced rapidly and has become a standard first-line treatment. A HIMALAYA study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the new immunotherapy combination STRIDE—tremelimumab and durvalumab compared with sorafenib. Dr. Lorenza Rimassa, the Principal Investigator from Humanitas University in Italy, was interviewed by us on site.
Interview with Dr. Michael Wang – Exciting Developments in Lymphoma Treatment! 

Interview with Dr. Michael Wang – Exciting Developments in Lymphoma Treatment! 

In a recent Hematology Frontier interview, Dr. Michael Wang shared insights from the EHA Late Breaker Plenary Session, where the pivotal ECHO clinical trial was discussed. the study is leading to breakthroughs in lymphoma care. The promising combination of BR + Acalabrutinib shows potential to improve outcomes, especially for older patients. This could pave the way for better therapies globally!
New Advances in Renal Cancer Treatment

New Advances in Renal Cancer Treatment

Excited to share this insightful talk with Dr. Liangyou Gu on tackling clear cell renal cell carcinoma with innovative approaches like neoadjuvant toripalimab. The future of kidney cancer treatment is evolving, and these advancements are offering real hope for better outcomes. Watch the video for key highlights!
Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive

Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive

The DESTINY-Gastric03 study (abstract number 14010), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), evaluated the efficacy and safety of T-DXd combined with FP and anti-PD-1 as first-line treatment for adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJA). At the conference site, we specially invited the Principal Investigator, Dr. Yelena Janjigian from Memorial Sloan Kettering Cancer Center in the United States, to be interviewed by us on site.